The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Targeted tumor profiling and actionable somatic variants in sarcoma.
 
Eytan Ben Ami
No Relationships to Disclose
 
Matthew Louis Hemming
No Relationships to Disclose
 
Michael Nathenson
No Relationships to Disclose
 
Katherine Anne Thornton
Consulting or Advisory Role - More Health; Novartis
Speakers' Bureau - Novartis
Travel, Accommodations, Expenses - Novartis
 
Priscilla Merriam
Consulting or Advisory Role - Lilly
 
Jeffrey A. Morgan
No Relationships to Disclose
 
Chandrajit P. Raut
No Relationships to Disclose
 
Suzanne George
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie (I)
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; deciphera
Research Funding - ARIAD (Inst); Bayer (Inst); Blueprint Medicines (Inst); Deciphera (Inst); Novartis (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - UptoDate
 
Andrew J. Wagner
Consulting or Advisory Role - Five Prime Therapeutics; Lilly; Loxo
Research Funding - AADi (Inst); Celldex (Inst); Daiichi Sankyo (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Plexxikon (Inst)
 
George D. Demetri
Leadership - Blueprint Medicines
Stock and Other Ownership Interests - Bessor Pharma; Blueprint Medicines; Caris Life Sciences; Champions Oncology; G1 Therapeutics; N-of-One
Consulting or Advisory Role - Adaptimmune; Bayer; Blueprint Medicines; Caris Life Sciences; Daiichi Sankyo; Eisai; EMD Serono; G1 Therapeutics; Genocea Biosciences; Janssen Oncology; Kolltan Pharmaceuticals; Kyocera; Lilly; Nektar; Novartis; Pfizer; PharmaMar; Polaris; Sanofi; WIRB-Copernicus Group; ZIOPHARM Oncology
Research Funding - Abbvie (Inst); Janssen Oncology (Inst)
Patents, Royalties, Other Intellectual Property - Patent on use of imatinib for GIST, receive minor royalty payment from Dana-Farber after license between Dana-Farber and Novartis